Neurocrine Bio. (NBIX) Bullish Stance Reiterated at Cowen
Get Alerts NBIX Hot Sheet
Rating Summary:
24 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Join SI Premium – FREE
Cowen analyst Phil Nadeau reiterated an Outperform rating and $55 price target on Neurocrine Bio. (NASDAQ: NBIX) after the company announced strongly positive Phase III data for '854 in Tardive Dyskinesia (TD). '854 (80 mg QD) reduced the AIMS score by 3.1 points vs. placebo (p<0.0001) in the ITT population.
Nadeau notes, "For comparison, competitor Teva's SD-809 produced a 1.4 point improvement in its Ph. III."
"We continue to think that NBIX is undervalued for '854 and Elagolix, and consider it a top small cap pick," he added.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $38.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Xeris Pharmaceuticals (XERS) at Outperform, 'successful commercial execution will continue to drive top-line growth'
- Oppenheimer Starts Immunovant (IMVT) at Outperform, 'expect the execution to unlock considerable value'
- HSBC Downgrades L'Occitane International SA (973:HK) (LCCTF) to Hold, 'risk reward ratio no longer compelling'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!